I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. Uliledlimab is the asset I-Mab has put ...
I-Mab (NASDAQ:IMAB) said on Monday that it is accelerating investment in its lead drug candidate, givastomig, a bispecific antibody for cancer treatment. The company plans to launch a global phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback